- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 09.10. | 1Spatial - Federal-level win in the US | 238 | 1Spatial's momentum in the US has continued, with the company securing a $1.4m deal with the United States Forest Service (USFS). This is a new Federal government-level deal for the business, building... ► Artikel lesen | ||
| 08.10. | IRLAB Therapeutics - IRL757 progress prompts $2.5m milestone payment | 257 | IRLAB Therapeutics has announced that it will receive a $2.5m milestone payment from the McQuade Center for Strategic Research and Development (MSRD), prompted by the dosing of the first participant... ► Artikel lesen | ||
| 08.10. | CI Games - Strategic roadmap to 2028 | 294 | CI Games outlined its updated strategy to 2028 at its H124 results. The strategy focuses on greater efficiencies to produce higher-quality games, while growing its audience base, and includes three... ► Artikel lesen | ||
| 07.10. | Actinogen Medical - Funding in place to complete XanaMIA Phase IIb | 217 | Actinogen Medical announced a capital increase of up to A$11.1m on 18 September, consisting of the successful completion of an A$8.1m (gross) share placement to existing shareholders and new institutional... ► Artikel lesen | ||
| 07.10. | Games Workshop Group - Sigmar the fourth | 359 | Games Workshop Group (GAW) is the global leader for tabletop miniature gaming, which has enjoyed impressive growth, with core revenue and total operating profit CAGRs of 17% and 19%, respectively, since... ► Artikel lesen | ||
| 04.10. | Card Factory - Confident on FY25 outlook | 337 | Card Factory's H125 revenue growth demonstrated it is delivering well against its multi-year growth strategy. While profitability was negatively affected by the (mostly) known inflation in operating... ► Artikel lesen | ||
| 04.10. | Immix Biopharma - US CAR-T trial progresses to dose expansion | 326 | Immix Biopharma's US-based NEXICART-2 trial continues to make steady progress through the clinic, with the company reporting that the trial has advanced to the dose expansion level of 450m cells, after... ► Artikel lesen | ||
| 03.10. | Helios Underwriting - Strategic shift from growth to consolidation | 341 | Helios Underwriting (Helios) delivered EPS growth of 35% to 7.7p in H124 and reported a net asset value (NAV) of 191p/share. While its combined ratio of 91.6% deteriorated from 88% in H123 and 85% in... ► Artikel lesen | ||
| 03.10. | Henderson Opportunities Trust - Taking AIM at the opportunity | 278 | With a focus on long-term growth, Henderson Opportunities Trust (HOT) seeks investment opportunities across the breadth of the UK market. This includes a strong bias towards smaller and earlier-stage... ► Artikel lesen | ||
| 03.10. | IRLAB Therapeutics - IRL757 starts strong in Phase I | 215 | IRLAB Therapeutics has announced an encouraging update for the ongoing Phase I trial for IRL757, which is being developed as a potential treatment for apathy. The single ascending dose (SAD) portion... ► Artikel lesen | ||
| 03.10. | Tetragon Financial Group - Tetragon maintains its investing pace | 260 | Tetragon Financial Group (Tetragon) reported a 1.3% return on equity (RoE) in H124, with its net asset value (NAV) per share increasing by 1.9% in US dollar total return (TR) terms, and further 3.8%... ► Artikel lesen | ||
| 02.10. | Cereno Scientific - CS1 shines in Phase IIa PAH trial | 255 | Cereno Scientific has reported positive top-line results for the Phase IIa CS1-003 trial, which evaluated the HDAC inhibitor CS1 in pulmonary arterial hypertension (PAH). The primary endpoint of safety... ► Artikel lesen | ||
| 02.10. | Gresham House Energy Storage Fund - Rising revenues and big plans for the future | 156 | Gresham House Energy Storage Fund (GRID) invests in utility-scale battery energy storage systems (BESS) in Great Britain. The sector had a tough start to the year, due to a deterioration in revenue... ► Artikel lesen | ||
| 02.10. | International Public Partnerships - FHSP partial realisation with £30m exit proceeds | 260 | International Public Partnerships (INPP) has announced the partial disposal of its Public-Private Partnerships (P3) investment providing family housing for US service personnel. The £30m proceeds take... ► Artikel lesen | ||
| 02.10. | Oryzon Genomics - FDA aligns on Phase III BPD plans | 297 | Oryzon Genomics has confirmed the FDA's alignment with its proposed Phase III programme for vafidemstat in borderline personality disorder (BPD). Notably, the FDA acknowledged agitation and aggression... ► Artikel lesen | ||
| 02.10. | Topps Tiles - Slight sequential improvement in Q424 | 236 | Topps Tiles (TPT) finished FY24 well on a relative basis by outperforming the still weak domestic repair, maintenance and improvement market. Its Q424 trading update indicates reassuring 'stable' trends... ► Artikel lesen | ||
| 01.10. | Greggs - Good Q324 on strong comparative | 332 | Greggs demonstrated continued strong sales growth in Q324, against a challenging Q323 comparative. The company continues to benefit from its multipronged growth strategy of increasing space, extended... ► Artikel lesen | ||
| 01.10. | SDCL Energy Efficiency Income Trust - Portfolio growth ahead of budget | 252 | SDCL Energy Efficiency Income Trust's (SEEIT's) interim update (for the six months to 30 September 2024) has highlighted that its operational assets, on a consolidated basis, are performing in line... ► Artikel lesen | ||
| 01.10. | IRLAB Therapeutics - Pirepemat Phase IIb trial completes enrolment | 222 | IRLAB Therapeutics has announced the completion of patient enrolment for the Phase IIb trial (React PD) assessing pirepemat's ability to improve balance and reduce falls in Parkinson's disease patients... ► Artikel lesen | ||
| 01.10. | Regional REIT - A clear strategy to realise value | 276 | Regional REIT's (RGL's) H124 performance had been well flagged during its equity raising and provided no surprises. With the £110.5m equity raise completed and the (£50m) retail bond repaid, investor... ► Artikel lesen | ||
| 30.09. | AFT Pharmaceuticals - Maxigesic IV reaches the Chinese shores | 180 | AFT Pharmaceuticals has taken another major step in extending its international footprint, with the signing of an exclusive license agreement for Maxigesic IV in China, the second-largest pharma market... ► Artikel lesen | ||
| 30.09. | Nano Dimension - Scaling up | 385 | Nano Dimension has agreed to acquire Markforged, a specialist in additive manufacturing (AM) for metal and advanced composites, for cash of $115m. The deal requires regulatory and Markforged shareholder... ► Artikel lesen | ||
| 27.09. | Pan African Resources - Analysing H224 and looking forward to FY25 | 316 | Pan African Resources' (PAF's) FY24 results, announced on 11 September, were within 1% of our prior forecasts for both EPS (4.14c cf 4.17c) and headline EPS (HEPS; 4.15c cf 4.17c). However, if the contract... ► Artikel lesen | ||
| 26.09. | Substrate AI - AI venture builder | 214 | Substrate AI buys, builds and scales ventures with proprietary artificial intelligence (AI) to transform companies across a range of sectors into AI driven businesses. Its core technology, Serenity... ► Artikel lesen | ||
| 26.09. | Greencoat Renewables - Efficient capital allocation and increasing demand | 359 | Greencoat Renewables' (GRP's) large and diversified pan-European portfolio of renewable energy assets generated net cash of €113.6m in H124 (H123: €125.5m). This equated to gross dividend cover of 3x... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
